COVID-19-related myocarditis and cholinergic anti-inflammatory pathways.
Hellenic J Cardiol
; 62(4): 265-269, 2021.
Article
in English
| MEDLINE | ID: covidwho-967843
ABSTRACT
Coronavirus disease-2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2, is currently in a pandemic outbreak and has become a global health issue. In addition to the primarily involvement of the respiratory system, myocarditis is considered an important and fatal lesion in patients with COVID-19. However, effective therapeutic methods are currently lacking. The cholinergic anti-inflammatory pathway (CAP) has been demonstrated to suppress pro-inflammatory cytokine production and control inflammation in sepsis and other medical conditions. Therefore, the CAP may be a potential and effective therapeutic method for COVID-19-related myocarditis. This article reviews the relationship between COVID-19-related myocarditis and the CAP and discusses the CAP as a potential therapeutic modality in the treatment of COVID-19-related myocarditis.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19
/
Myocarditis
Limits:
Humans
Language:
English
Journal:
Hellenic J Cardiol
Journal subject:
Cardiology
Year:
2021
Document Type:
Article
Affiliation country:
J.hjc.2020.12.004
Similar
MEDLINE
...
LILACS
LIS